Skip to main content
OpenTrials
Completed

NCT Number: NCT03376360

Functional Medical Imaging Quantization in Prostate Cancer

Prostate cancer is the most common cancer in men over 50 years old and the third leading cause of cancer death. Because of the variety of prostate cancers, different treatments exist.

Several criteria guide this management in daily practice: PSA level; TNM stage (digital rectal examination, trans-rectal ultrasound and classical visual imaging) and pathological differentiation with the Gleason score, to which can be added other prognostic criteria: growth and doubling time of the serum PSA, number of positive biopsies and percentage of cancer lesions by biopsy.

Functional imaging by PET and MRI is increasingly used in daily clinical practice to characterize prostate cancer, either during initial discovery or during recurrence. In this context, it is the qualitative visual analysis that is mainly used. Quantitative image analysis could add new criteria to guide patient management.

Consequently, the objective of this study were:

* Optimization of 18F-choline PET/CT Acquisition in Prostate Cancer * Comparison the quantitative parameters obtained by 18F-Choline PET / CT and both perfusion MRI and histological parameters.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Prostate Cancer Genital Diseases Genital Diseases, Male Genital Neoplasms, Male Male Urogenital Diseases Neoplasms Neoplasms by Site Prostatic Diseases Prostatic Neoplasms Urogenital Diseases Urogenital Neoplasms

Age range

18 year and older

Sex eligibility

Male

Study type

Observational

Primary location

CHRU de Brest

Brest, 29609, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with prostate cancer histologically proven included in Brest University Hospital between 01/07/2012 and 01/10/2015 and underwent F-choline PET/CT and pelvic MRI Patient consent

Exclusion criteria

No lesion on dynamic acquisition on PET/CT and/or on pelvic MRI

Treatment and study plan

Primary outcomes

  1. correlation between Gleason score and dynamic parameters on PET and MRI

    Time frame: when anatomopathological report is available, an average of 3 months after the PET/CT

    study the potential correlation between dynamic parameters on PET and MRI

Secondary outcomes

  1. reconstructions on 18F-choline PET

    Time frame: when all 18F-choline PET are performed, an average of 6 months

    determine the mean influx from each reconstruction which is the closest to the objective value

  2. best "fitting" on PET and MRI

    Time frame: when all MRI are performed, an average of 6 months

    the Akaike Criteria Information was chose to choose the best fit

  3. comparison between data (PSA, TNM stage, EFS and OS)

    Time frame: 01/05/2017

    comparison between data (PSA, TNM stage, EFS and OS)

Sponsors and collaborators

Lead sponsor

University Hospital, Brest

Other

Registry information

Official study title

Optimization of 18F-choline PET/CT Acquisition in Prostate Cancer: Preliminary Results Concerning the Length of the Acquisition

Acronym: QUIP

Important dates

Study start
2015
Primary completion
2017
Study completion
2017
First posted
Dec 18, 2017
Registry last updated
Aug 15, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.